Last updated: April 26, 2026
Israel Patent IL278178: Scope, Claims, and Landscape Impact
What is IL278178 (and what does it cover)?
IL278178 is an Israeli patent publication registered under the Israel Patent Office. The patent’s scope must be assessed through the exact claim set and the disclosed embodiments in the specification. Without the full, authoritative text of IL278178 (claims and description), an accurate, claim-by-claim scope mapping cannot be produced.
What does the claim set likely look like (and what can be concluded)?
A complete analysis requires:
- Independent claims and their claim limitations (for example, drug compound structure, salt form, polymorph, formulation, dosing regimen, patient group, route, and manufacturing parameters).
- Dependent claims that narrow scope and indicate specific design-arounds.
- The specification’s “support” for key features, which affects claim interpretation in Israel.
No claim-level content is provided here, and IL278178 claim text is not included in the prompt. Per operational constraints, the analysis cannot proceed without producing a complete and accurate response.
Where does IL278178 sit in the broader patent landscape?
A landscape-grade view depends on:
- Priority data (earliest priority filing, continuation/divisional status).
- Claim scope overlap with key international family members (EP/WO/US filings).
- Patent term and exclusivity signals in Israel (in particular, whether the effective term or any linkage affects enforceability).
- Whether there are competing filings in Israel covering the same active ingredient, crystalline form, salt, or formulation.
No family/priority details, citation history, or Israel-specific prosecution history for IL278178 is included in the prompt. Without that, any “landscape” mapping would be speculative.
What are the enforceable boundaries in Israel (claim construction in practice)?
Enforceable boundaries depend on:
- Literal infringement: matching every limitation in at least one independent claim.
- Doctrine of equivalents (where applied): Israel’s approach is not identical to US or EU practice and still turns on claim language and prosecution history.
- Claim interpretation: Israeli courts interpret claims in light of the description and drawings, and the “essential features” test can become decisive when claims are drafted broadly.
A claim-by-claim construction is impossible without the actual claim language.
Key Takeaways
- A complete scope and claims analysis for IL278178 cannot be produced from the information provided because the claim text and specification content are not present.
- Landscape positioning also cannot be completed without IL278178 priority/family data and Israel-specific claim scope information.
- Any attempt to fill gaps would risk producing inaccurate boundaries and erroneous freedom-to-operate implications.
FAQs
-
Can I get a claim-by-claim scope chart for IL278178 without the claim text?
No. Scope mapping requires the exact claim limitations.
-
How do Israel courts interpret drug patent claims?
Interpretation is tied to claim language read in light of the description and drawings, with infringement analyzed against every claim limitation.
-
What determines design-around options for a drug formulation patent in Israel?
The dependent claim feature set (salt/polymorph/formulation/dosing/route) and how broadly independent claims are written.
-
Does IL278178’s family determine its Israeli strength?
Yes, but only once priority and corresponding foreign claim scope are identified.
-
What information is required to build a reliable landscape for IL278178?
Priority and family mappings, the full claim set, and Israel-specific prosecution/publication details.
References
- Israel Patent Office. IL278178 (publication and legal status record). (Not provided in the prompt.)
- World Intellectual Property Organization. WO/EP/US family records for IL278178 (if applicable). (Not provided in the prompt.)
